Compare Stocks

Date Range: 

 Ener-CoreGlyEcoSummit EnvironmentalHighCom Global SecurityArtemis Therapeutics
SymbolOTCMKTS:ENCROTCMKTS:GLYEOTCMKTSMKTS:SEVTOTCMKTS:HCGSOTCMKTS:ATMS
Price Information
Current Price$0.05$0.05N/A$0.01$2.53
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.50.50.00.50.5
Analysis Score0.00.00.00.00.0
Community Score2.52.50.02.32.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$200,000.00$68,000.00N/A$4.54 million$13.04 million
Beta3.117.141.790.360.36
Average Volume10,8122,9745,360150,4435,992
Sales & Book Value
Annual RevenueN/A$6.46 millionN/A$7.48 millionN/A
Price / SalesN/A0.01N/A0.60N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/AN/AN/A($0.07) per share
Price / BookN/AN/AN/A
Profitability
Net IncomeN/A$-5,310,000.00N/A$110,000.00$-120,000.00
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/A-591.30%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/A0.01%
Quick RatioN/AN/AN/AN/A0.01%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership Percentage3.81%22.70%N/A16.00%7.45%
Miscellaneous
Employees1018N/A19N/A
Shares Outstanding4.08 million1.43 millionN/A386.01 million5.15 million
Next Earnings DateN/AN/AN/AN/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Artemis Therapeutics (OTCMKTS:ATMS)  Shares Down 5.7% Artemis Therapeutics (OTCMKTS:ATMS) Shares Down 5.7%
americanbankingnews.com - June 10 at 12:18 AM
LendingPoint Recognized by Atlanta Business Chronicle’s Pacesetter Award for Fourth Consecutive YearLendingPoint Recognized by Atlanta Business Chronicle’s Pacesetter Award for Fourth Consecutive Year
in.finance.yahoo.com - April 30 at 4:43 PM
Caution: Most Stocks Fail! Do This to Build a Winning Stock PortfolioCaution: Most Stocks Fail! Do This to Build a Winning Stock Portfolio
ca.finance.yahoo.com - April 30 at 4:43 PM
Essex Communities Announces New Leadership Structure to Accommodate Rapid GrowthEssex Communities Announces New Leadership Structure to Accommodate Rapid Growth
au.finance.yahoo.com - April 29 at 1:09 PM
‘The Falcon and Winter Soldier’ fails to pay off on its initial promise‘The Falcon and Winter Soldier’ fails to pay off on its initial promise
au.finance.yahoo.com - April 29 at 1:09 PM
Another piebald deer stops by a trail camera for a photoAnother piebald deer stops by a trail camera for a photo
yahoo.com - March 25 at 7:16 AM
Mum selling her possessions to fund £35K surgery before rare condition leaves her paralysedMum selling her possessions to fund £35K surgery before rare condition leaves her paralysed
yahoo.com - March 25 at 7:16 AM
Lineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% UpsideLineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% Upside
seekingalpha.com - November 18 at 3:07 PM
FTSE 100 falls on day and over week as US, China fears ripple through marketsFTSE 100 falls on day and over week as US, China fears ripple through markets
www.proactiveinvestors.co.uk - July 26 at 7:27 PM
Artemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral InfectionsArtemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral Infections
finance.yahoo.com - January 21 at 3:44 PM
New Data Demonstrate Artemis Therapeutics Artemisone May Be An Effective Inhibitor Of Human CMV ReplicationNew Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
finance.yahoo.com - January 21 at 3:44 PM
Data Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics Artemisone May Be An Effective Inhibitor Of Human CMV ReplicationData Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
finance.yahoo.com - January 21 at 3:44 PM
Artemis Therapeutics Announces Two Recent Publications Highlighting Artemisones Activity Against Human Cytomegalovirus And MalariaArtemis Therapeutics Announces Two Recent Publications Highlighting Artemisone's Activity Against Human Cytomegalovirus And Malaria
finance.yahoo.com - January 21 at 3:44 PM
DateCompanyBrokerageAction
(Data available from 6/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.